187 related articles for article (PubMed ID: 33881356)
1. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
Kabra M; Margotto L; Manuguid F
Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.
Griffin JD; Yang H; Song Y; Kinrich D; Shah MV; Bui CN
Eur J Haematol; 2019 Apr; 102(4):341-350. PubMed ID: 30578743
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
Villa KF; Ryan RJ; Chiarella M; Louie AC
J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
[No Abstract] [Full Text] [Related]
4. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
5. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
6. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
7. A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life.
Lowe JR; Yu Y; Wolf S; Samsa G; LeBlanc TW
J Palliat Med; 2018 May; 21(5):592-597. PubMed ID: 29341836
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.
Medeiros BC; Pandya BJ; Hadfield A; Pike J; Wilson S; Mueller C; Bui CN; Flanders SC; Rider A; Horvath Walsh LE
Curr Med Res Opin; 2019 May; 35(5):927-935. PubMed ID: 30712406
[TBL] [Abstract][Full Text] [Related]
9. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
11. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
[TBL] [Abstract][Full Text] [Related]
12. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
16. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
18. Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy.
Lachowiez C; Kearney M; Meyers G; Maziarz RT; Cook RJ
Leuk Lymphoma; 2019 Nov; 60(11):2817-2820. PubMed ID: 31056994
[No Abstract] [Full Text] [Related]
19. How I treat refractory and early relapsed acute myeloid leukemia.
Thol F; Schlenk RF; Heuser M; Ganser A
Blood; 2015 Jul; 126(3):319-27. PubMed ID: 25852056
[TBL] [Abstract][Full Text] [Related]
20. How I treat relapsed or refractory AML.
DeWolf S; Tallman MS
Blood; 2020 Aug; 136(9):1023-1032. PubMed ID: 32518943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
